In the 1st line therapy of metastatic colorectal cancer(mCRC), SOX+Bevacizumb(Bev) regimen (L-OHP: 130 mg/m2 day 1, Bev: 7.5 mg/kg day 1, S-1: 80, 100, 120 mg*/body days 1–14 repeated every 3 weeks, *According to body surface area, BSA < 1.25 m2, BSA ≥ 1.25 to
This trial is an open-label, multi-center, phase 2 study. Before administration of SOX regimen, Ccr is measured. The patients with Ccr >_70, the standard dose will be administered, and in the patients with Ccr 70>_60, the level 1 dose control (decrease) will be performed, and in the patients with Ccr 60>_50, the level 2 dose control will be performed (in the patients
Clinical trial identification
Legal entity responsible for the study
Kyoto Katsura Hospital
All authors have declared no conflicts of interest.